Combined ivermectin and intense pulsed light therapy can help resolve Demodex blepharitis and prevent its recurrence.

This article highlights clinical and economic factors associated with Demodex blepharitis as well as diagnostic complexities, limitations of traditional therapies, the safety and efficacy of the 1 ...

Tarsus is developing its lead candidate TP-03, potentially the first FDA-approved therapy for Demodex blepharitis, and a pipeline of investigational therapies targeting eye care, dermatology ...

An expert provides insights into the cost of misdiagnosed Demodex blepharitis and payer considerations for a potential cost-effective treatment. Eric D. Donnenfeld, MD; underscores the ...

if the diagnosis is Demodex blepharitis, prescribe a treatment. "Proper management can significantly improve your symptoms," Watson emphasizes. Most common side effects: The most common side ...

Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as ...

The company's strategic moves appear to be setting the stage for sustained progress in the treatment of Demodex blepharitis. While analysts project continued sales growth, detailed financial ...